Cardiorentis AG
Developing drug therapies for the treatment of acute heart failure and related cardiovascular diseases
Cardiorentis AG is a privately owned biopharmaceutical company designed for the new world of drug development. Focused, fast moving and flexible, with patients at its heart, Cardiorentis AG is committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
13.01.2016
Cardiorentis raises CHF 60 Million in series B financing (startupticker.ch)
04.01.2016
Cardiorentis’ Ularitide Receives FDA Fast Track Designation (startupticker.ch)
18.09.2014
Cardiorentis Announces Euro 45 Million Financing with HealthCare Royalty Partners (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Cardiorentis AG
Developing drug therapies for the treatment of acute heart failure and related cardiovascular diseases
Website:
www.cardiorentis.com
Headquarter:
Foundation Date:
April 2010
Technology:
- Biotech
Sectors:
- Drug development platforms
- Drug discovery